新动生物宣布完成数千万天使轮融资，助力宠物创新药开发

Core Viewpoint - The investment by Guanggu Chantuo in Wuhan Xindong Biotechnology Co., Ltd. marks a significant step in enhancing the capabilities of the pet pharmaceutical industry in China, focusing on innovative CRO services for pet drug development [1] Company Summary - Wuhan Xindong Biotechnology, established in 2023, specializes in providing evaluation services for pet drug development, offering a comprehensive R&D service solution that includes model animals, preclinical, and clinical research [1] - The funding will primarily be used for the expansion of experimental animal facilities and the continuous improvement of disease models and technology platforms [1] - The company aims to create a one-stop R&D service platform addressing core client pain points, enhancing R&D efficiency, reducing overall R&D costs, and accelerating the development and transformation of innovative pet drugs [1] Industry Summary - The investment is expected to promote the advancement of the domestic pet pharmaceutical industry, contributing to the establishment of a more vibrant life and health industry ecosystem in China [1]